brincidofovir (cmx001) is an experimental antiviral drug being developed by chimerix of durham, nc, for the treatment of cytomegalovirus, adenovirus, smallpox, and ebolavirus infections. brincidofovir is a prodrug of cidofovir. conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsdna viruses, as well as oral bioavailability.